How Much Does Retatrutide Cost?

Published on December 12, 2025 | Prices Last Reviewed for Freshness: January 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer.

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and early trials suggest very strong weight loss effects, with average reductions of about 24 percent at higher doses over 48 weeks in people with obesity. A 2024 Nature Medicine study reported greater weight loss than current GLP-1 drugs, which helps explain why interest in retatrutide cost has surged even before formal approval. People with obesity or type 2 diabetes, weight loss clinics and researchers all want to understand what this new therapy might mean for their budget and for future treatment planning.

As of late 2025, there is no official retail retatrutide price because the drug is still in clinical trials and does not yet have a commercial brand name or FDA approval in the United States. What exist instead are two very different price worlds. One is the research peptide market, where laboratories buy small vials of retatrutide at per-milligram rates. The other is a small but growing set of wellness and obesity clinics that offer “retatrutide style” injections within medical weight loss programs, usually as cash-pay packages. Because there is no approved brand yet, any “retatrutide-style” offer should be treated as experimental or compounded, and patients need to be clear about what active ingredient is actually being used so they do not face a surprise bill or unregulated product.

This guide walks through both realities of retatrutide cost. It summarizes current research-grade pricing per vial, early clinic program fees per month, how those numbers add up over time, which factors move prices up or down and how retatrutide compares financially with established injectables such as semaglutide and tirzepatide. Throughout, it is important to remember that retatrutide remains experimental and any use for weight loss or diabetes should occur only in a regulated setting under the care of a licensed clinician.

Article Highlights

• Retatrutide is still an investigational drug, so all current prices reflect research supply costs or cash-pay clinical programs rather than a final retail list price.
• Research peptide suppliers list retatrutide at about $28–$32 per mg and roughly $269–$350 per 10 mg vial, which shows how expensive the raw molecule is to produce even before clinical overhead is added.
• Early clinic programs for weight loss often charge between about $800 and $2,400 per month, usually bundling medical visits and lab monitoring into that fee.
• Real household out-of-pocket costs also include consultation fees, laboratory tests, supplies and medications to manage side effects, which can add several hundred dollars over a few months.
• Compared with approved injectables like semaglutide and tirzepatide, retatrutide currently sits at the higher end of the price spectrum and lacks consistent insurance coverage.
• Anyone considering retatrutide for weight management should discuss options with a licensed clinician, verify exactly which drug is being used, and be cautious about unregulated “research” products marketed directly to consumers.

How Much Does Retatrutide Cost?

Most hard price data available in 2025 comes from laboratories that sell retatrutide as a research chemical, not as a finished prescription drug. A detailed pricing survey from the peptide supplier KiloBio lists small 1 mg aliquots at about $28–$32, 5 mg vials at roughly $139–$159 and 10 mg vials between $269 and $350, with 50 mg bulk packs running around $1,199–$1,399 as of early 2025. These prices are wholesale research rates and are clearly labeled “not for human use,” yet they set an anchor for how costly the retatrutide molecule itself is to manufacture.

Early clinical and wellness programs that advertise retatrutide injections usually do not sell the vials directly. Instead, they bundle the medication with physician consults, lab work and coaching into monthly packages.

A Connecticut weight loss clinic, LIVation, quotes retatrutide program pricing in the range of about $800–$2,400 per month depending on dose, monitoring intensity and support services, as of 2025. The clinic notes that this covers the medication as well as ongoing care. In practice, that makes retatrutide one of the most expensive injectable weight loss options on a cash-pay basis, although the range partly reflects customized dosing and bundled services.

Because retatrutide has not yet reached standard retail pharmacies, there is no published “list price” comparable to the wholesale acquisition cost seen for Wegovy or Zepbound. Any retatrutide cost figure today reflects either research supply economics or self-pay clinic programs. Health insurers generally do not reimburse these uses, so people participating in off-label or experimental programs are usually responsible for the full bill, and they should expect higher monthly totals than they might see once an FDA-approved version is on the market with formal insurance pathways.

Real-life cost examples

To understand how retatrutide pricing plays out in practice, it helps to look at concrete scenarios. Consider a medically supervised weight loss program in a U.S. metro area that offers weekly retatrutide injections for people with obesity who do not qualify for or tolerate existing GLP-1 treatments. A typical package might quote $1,200 per month, including the drug itself, monthly physician follow ups and basic laboratory blood work every 3 months. Over a 6 month period, that single program structure would produce a total bill in the region of $7,200, not including any extra visits for side effects.

Another scenario involves a higher-touch concierge clinic that positions retatrutide as a premium, last-line intervention. LIVation in Connecticut reports that its higher dose, more intensive monitoring tier can approach $2,400 per month for retatrutide-based care, with additional fees for outside labs or nutrition counseling. A RealSelf explainer on the drug cites similar figures for early clinic adopters and emphasizes that pricing varies by provider and region. In that kind of program, a 6 month course can quickly exceed $10,000.

Also read our articles on other weight loss drugs like Ozempic, Wegovy, or Zepbound.

Retail and mail-order peptide suppliers provide a different type of cost example, though not a recommended route for patient self-treatment. A 10 mg vial listed by one U.S. research vendor currently sells for around $180, and another supplier ranges between about $89 and $640 depending on concentration and packaging. ModernPeptides and similar companies stress that these products are “for laboratory research only,” yet they illustrate how raw material prices can look much lower than fully supervised clinical service pricing. For patients, the key point is that lower research prices do not mean it is safe, legal, or appropriate to self-inject these products.

These case snapshots show a wide spectrum. A researcher might purchase a single vial for under $300, while a patient in a high-touch weight management clinic can face bills of several thousand dollars over only a few months. The gap reflects much more than drug cost alone: it includes professional time, lab monitoring, infrastructure and the risk premium of using an investigational therapy.

Cost breakdown

The total cost of retatrutide therapy can be separated into several billable components. First is the base drug price, which is the figure closest to those per-milligram numbers from research suppliers and which will someday correspond to whatever list price Eli Lilly sets once the drug is approved. Current research peptide listings, such as a 10 mg vial from Peptide Sciences, sit in the low hundreds of dollars, typically between about $180 and $300 per vial depending on dose and supplier. Clinics then add their own acquisition costs when they purchase through regulated channels or compounders.

The second layer involves professional services. Clinics charge new-patient consultations that commonly run between $150 and $350 per visit, then shorter follow up visits in the $75–$200 range. Programs that bundle “unlimited follow ups” often roll those fees directly into monthly retatrutide cost, which pushes the subscription figure upward but can offer predictable budgeting.

Laboratory monitoring is another significant component, particularly in early months. Comprehensive metabolic panels, lipid profiles and A1c testing often add $100–$300 every few months when billed cash price, with more advanced panels or repeated testing pushing those totals higher. Some clinics have negotiated lab rates and package these tests; others send patients to outside labs where insurance coverage determines the out-of-pocket share.

Supplies and logistics usually represent the smallest share of the overall retatrutide cost, yet they still matter for household budgets. Syringes, alcohol swabs and sharps containers add perhaps $10–$40 per month, while shipping or specialty pharmacy delivery fees contribute another $10–$25 when home delivery is used. Hidden costs include prescription anti-nausea medications or treatment for gastrointestinal side effects, which can add another $20–$100 in a given month and are rarely advertised in headline prices.

Putting these elements together, a person in a moderate-priced clinic paying about $1,000 monthly for retatrutide might effectively be covering $300–$400 in medication, $200–$300 in professional visits, $100–$200 in lab work and $50–$75 in supplies and ancillary drugs during the most intensive phase. This worked example is only an illustration, yet it matches the broad structure reported by early retatrutide programs and shows why the final bill looks very different from the raw peptide price alone.

Factors influencing the cost

Several forces push retatrutide pricing higher than many existing metabolic drugs. At the molecule level, a triple-agonist peptide is technically complex to synthesize and purify, and KiloBio’s pricing analysis notes that the raw material cost per 10 mg for retatrutide is more than double that of semaglutide, with base synthesis costs around $185 versus roughly $79 for a semaglutide equivalent. This chemical complexity, combined with relatively low production volume so far, limits opportunities for economies of scale.

To illustrate the scale of drug usage in trials, high-dose arms in the 48-week obesity study used weekly doses up to 8–12 mg. That translates into roughly 384–576 mg of retatrutide per participant over the course of a year-long protocol. If you hypothetically applied research pricing of about $28–$32 per milligram to that quantity, the raw peptide value alone would fall somewhere in the $10,000–$18,000 range for a single high-dose course. This does not represent a future pharmacy price, but it highlights why manufacturing cost, dose strength and treatment duration all matter when estimating eventual real-world retatrutide cost.

Another major factor is market excitement. Clinical data presented in Nature Medicine and investor communications from Eli Lilly show that retatrutide delivered average weight loss up to about 24 percent in people with obesity, greater than what has been seen in many head-to-head comparisons with current GLP-1 and dual agonist drugs. Strong efficacy expectations raise the ceiling on what payers and patients may be willing to pay once the drug is fully launched and insurers start negotiating coverage and rebates.

Regulatory status also matters. Because retatrutide is still in trials and has not received FDA approval as of late 2025, there is no generic competition and no legal pathway for broad insurance reimbursement. Clinics that offer early access programs operate in a narrow space where they typically must source the peptide through compounding or research channels and then charge patients directly. Once an official branded product arrives, insurers will decide whether and how to cover it, and those decisions will strongly shape future out-of-pocket retatrutide cost and whether it resembles current GLP-1 pricing or sits in a premium tier.

Finally, broader economic conditions influence pricing. Inflation in healthcare labor, rising rents for clinical space and higher regulatory compliance expenses all drive up program fees. At the same time, Eli Lilly is investing heavily in new manufacturing capacity for incretin drugs, which could moderate long-term production costs but will have to be balanced against shareholder expectations for revenue growth and any future price competition from other triple agonists.

Alternative products or services

People researching retatrutide pricing often compare it to the cost of established GLP-1 and dual agonist medications. Semaglutide, sold as Wegovy for obesity and Ozempic for diabetes, and tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, already have list prices, insurance pathways and manufacturer savings programs. A recent overview of weight loss injectables from Noom’s medical team reports that semaglutide weight loss therapy often starts around $499 per month in discounted self-pay programs, while tirzepatide programs fall in a broad band between about $349 and $1,000 monthly depending on dose, pharmacy and coverage. Manufacturer price cuts in 2024–2025 have brought some starter doses of Wegovy and Zepbound closer to the $349–$499 range for self-pay patients, though clinic-packaged programs with labs and coaching can still climb toward four figures.

Against that backdrop, retatrutide looks both promising and expensive. Research peptide vials may cost under $300 each, yet clinical programs that bundle the drug with comprehensive care often price a month of treatment at or above the upper end of current GLP-1 options. The absence of insurer support further widens the effective gap, since many patients using Wegovy or Zepbound qualify for copay cards or partial reimbursement that can lower their real monthly payment far below the nominal list price.

For quick comparison, the table below summarizes typical self-pay ranges reported in late 2024 and 2025.

The figures for semaglutide and tirzepatide come from manufacturer list prices combined with clinic program data, while retatrutide ranges draw on both research peptide suppliers and early clinical offerings. In practice, anyone choosing between these treatments should weigh not only drug cost but also efficacy, side effect profiles, availability and the strength of evidence for long-term safety.

Answers to Common Questions

Is retatrutide available as a regular prescription yet?

No. As of 2025 retatrutide remains in clinical trials and has not received FDA approval, so there is no standard retail prescription product at community pharmacies. Access is mainly through research settings and experimental or compounding-based clinic programs.

Why does retatrutide seem more expensive than Wegovy or Zepbound?

The molecule is more complex to synthesize, manufacturing is still at relatively small scale and there is strong demand driven by very promising trial results. In addition, most current use is cash-pay, so patients do not benefit from the insurance and coupon structures that reduce effective costs for approved drugs. Until insurers and manufacturers negotiate formal coverage and discounts, retatrutide clinic programs will tend to sit at a premium price.

Can insurance cover retatrutide cost today?

Major health plans typically restrict coverage to FDA-approved medications, so they do not cover research peptide products and rarely reimburse experimental clinic programs centered on retatrutide. Once an approved brand launches, insurers will reassess coverage based on clinical data, guidelines and negotiated pricing, which could significantly change out-of-pocket cost compared with today’s cash-only programs.

Is it cheaper to buy retatrutide from online peptide sites?

Research suppliers often list per-vial prices far below clinic program fees, but their products are sold for laboratory use only and are not manufactured, tested or labeled for self-injection in humans. Using them as medication carries significant safety, quality and legal risks and is not recommended, even if the sticker price looks lower than a supervised medical program.

How can patients manage costs if retatrutide is approved?

If and when a branded retatrutide product is approved, patients can ask about insurance coverage, manufacturer savings cards, income-based assistance programs and whether lower-cost alternatives such as semaglutide or tirzepatide would offer similar benefits for their situation. A prescribing clinician or pharmacist can help compare options and look for ways to minimize out-of-pocket expenses without compromising safety.